Cargando…
Efficacy and safety of oral hydroxyurea in transfusion-dependent β-thalassaemia: a protocol for randomised double-blind controlled clinical trial
INTRODUCTION: Despite being one of the first diseases to be genetically characterised, β-thalassaemia remains a disorder without a cure in a majority of patients. Most patients with β-thalassaemia receive only supportive treatment and therefore have a poor quality of life and shorter life spans. Hyd...
Autores principales: | Yasara, Nirmani, Wickramarathne, Nethmi, Mettananda, Chamila, Manamperi, Aresha, Premawardhena, Anuja, Mettananda, Sachith |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7592299/ https://www.ncbi.nlm.nih.gov/pubmed/33109679 http://dx.doi.org/10.1136/bmjopen-2020-041958 |
Ejemplares similares
-
A randomised double-blind placebo-controlled clinical trial of oral hydroxyurea for transfusion-dependent β-thalassaemia
por: Yasara, Nirmani, et al.
Publicado: (2022) -
A comprehensive review of hydroxyurea for β-haemoglobinopathies: the role revisited during COVID-19 pandemic
por: Yasara, Nirmani, et al.
Publicado: (2021) -
Psychometric evaluation of the NTDT-PRO questionnaire for assessing symptoms in patients with non-transfusion-dependent beta-thalassaemia
por: Taher, Ali T, et al.
Publicado: (2023) -
Body iron status of children and adolescents with transfusion dependent β-thalassaemia: trends of serum ferritin and associations of optimal body iron control
por: Suriapperuma, Tharindi, et al.
Publicado: (2018) -
Mutation screening for thalassaemia in the Jino ethnic minority population of Yunnan Province, Southwest China
por: Wang, Shiyun, et al.
Publicado: (2015)